Huidagene, Merck Moderna vaccine, FDA: Readout Newsletter

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’re sending the newsletter a bit early today since we’ve got some breaking news for you — plus a new FDA commissioner nominee.

Merck and Moderna’s mRNA cancer vaccine succeeds in late-stage trial

Scientists have long hoped that personalized mRNA cancer vaccines could be the next big breakthrough in oncology treatment. Today, Merck and Moderna said they had shown in a randomized late-stage trial for the first time that such a drug can work.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

View All Plans